191 related articles for article (PubMed ID: 31571127)
1. Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use.
Lamb YN
Clin Drug Investig; 2019 Nov; 39(11):1141-1147. PubMed ID: 31571127
[TBL] [Abstract][Full Text] [Related]
2. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.
Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM
Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409
[TBL] [Abstract][Full Text] [Related]
3. Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis.
Nwannunu CE; Limmer AL; Coleman K; Shah R; Patel RR; Mui UN; Tyring SK
Skin Therapy Lett; 2019 Mar; 24(2):1-3. PubMed ID: 30970203
[TBL] [Abstract][Full Text] [Related]
4. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: A randomized, double-blind, vehicle-controlled study.
Yokozeki H; Fujimoto T; Wanatabe S; Ogawa S; Fujii C
J Dermatol; 2022 Jan; 49(1):86-94. PubMed ID: 34636057
[TBL] [Abstract][Full Text] [Related]
5. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.
Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok R; Drew J; Quiring J; Pariser DM
J Am Acad Dermatol; 2019 Jan; 80(1):128-138.e2. PubMed ID: 30003988
[TBL] [Abstract][Full Text] [Related]
6. Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis.
Pariser DM; Lain EL; Mamelok RD; Drew J; Mould DR
Clin Pharmacokinet; 2021 May; 60(5):665-676. PubMed ID: 33433785
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.
Hebert AA; Glaser DA; Green L; Hull C; Cather J; Drew J; Gopalan R; Pariser DM
Pediatr Dermatol; 2020 May; 37(3):490-497. PubMed ID: 32147881
[TBL] [Abstract][Full Text] [Related]
8. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.
Pariser DM; Hebert AA; Drew J; Quiring J; Gopalan R; Glaser DA
Am J Clin Dermatol; 2019 Feb; 20(1):135-145. PubMed ID: 30378087
[TBL] [Abstract][Full Text] [Related]
9. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
Hebert AA; Glaser DA; Green L; Werschler WP; Forsha DW; Drew J; Gopalan R; Pariser DM
Pediatr Dermatol; 2019 Jan; 36(1):89-99. PubMed ID: 30451318
[TBL] [Abstract][Full Text] [Related]
10. Qbrexza - A glycopyrronium cloth for axillary hyperhidrosis.
Med Lett Drugs Ther; 2019 Jan; 61(1564):10-11. PubMed ID: 30856158
[No Abstract] [Full Text] [Related]
11. Use of gloves when applying topical glycopyrronium for treatment of primary axillary hyperhidrosis.
Siscos SM; Figenshau K; Rajpara A
J Am Acad Dermatol; 2020 Oct; 83(4):e275. PubMed ID: 31846717
[No Abstract] [Full Text] [Related]
12. Glycopyrronium (Qbrexza) Topical Wipes for Hyperhidrosis.
Arnold MJ; O'Connor C
Am Fam Physician; 2019 Sep; 100(6):372-373. PubMed ID: 31524358
[No Abstract] [Full Text] [Related]
13. Variables Affecting Delivery of Glycopyrronium Tosylate Through Human Skin In Vitro.
Caserta F; Lenn J; Hofland H
J Drugs Dermatol; 2020 Nov; 19(11):1080-1085. PubMed ID: 33196749
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis.
Bloudek LM; Gillard KK; Nguyen VB; Klein SZ
J Med Econ; 2021; 24(1):29-37. PubMed ID: 33256494
[TBL] [Abstract][Full Text] [Related]
15. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial.
Abels C; Soeberdt M; Kilic A; Reich H; Knie U; Jourdan C; Schramm K; Heimstaedt-Muskett S; Masur C; Szeimies RM
Br J Dermatol; 2021 Aug; 185(2):315-322. PubMed ID: 33445205
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study.
Hyun MY; Son IP; Lee Y; Choi HG; Park KY; Li K; Kim BJ; Seo SJ; Kim MN; Hong CK
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):278-282. PubMed ID: 24909188
[TBL] [Abstract][Full Text] [Related]
17. Topical glycopyrrolate reduces axillary hyperhidrosis.
Baker DM
J Eur Acad Dermatol Venereol; 2016 Dec; 30(12):2131-2136. PubMed ID: 27406319
[TBL] [Abstract][Full Text] [Related]
18. Urinary retention and mydriasis secondary to topical glycopyrronium for axillary hyperhidrosis.
Green HH; Ray L; Buchanan J; Matsler N
Am J Health Syst Pharm; 2023 Sep; 80(18):1234-1237. PubMed ID: 37348110
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of iontophoresis with glycopyrronium bromide for treatment of primary palmar hyperhidrosis.
Chia HY; Tan AS; Chong WS; Tey HL
J Eur Acad Dermatol Venereol; 2012 Sep; 26(9):1167-70. PubMed ID: 21812834
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial.
Kirsch B; Smith S; Cohen J; DuBois J; Green L; Baumann L; Bhatia N; Pariser D; Liu PY; Chadha D; Walker P
J Am Acad Dermatol; 2020 Jun; 82(6):1321-1327. PubMed ID: 32068049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
